REMUS

What Remus Pharma. promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q2 FY26

what the last two calls moved 7 tracked 1 delivered 2 missed 4 open
  • Revenue Growth delivered said Q4 FY25 Promised: we will see a sustainable growth in the revenue, which we will see in the next coming year [FY26] (not exorbitant like 191%) Q2 FY26: H1 FY26 revenue grew at a sustainable 47% YoY, aligning perfectly with the narrative of normalizing growth.
  • B2C Business Share missed said Q4 FY25 Promised: by end of this year [FY25], we will have at least 25% to 30% of B2C business Q2 FY26: H1 FY26 actual is only 13%. Management revised the target down to 18-20% by the end of FY26.
  • Semaglutide-like Commercialization on track said Q4 FY25 Promised: those sales and revenues will also be coming pretty soon, probably H2 [FY26] is what we are aiming. Q2 FY26: Not explicitly mentioned, but the timeline (H2 FY26) has not yet arrived.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 7 tracked commitments for Remus Pharma. — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens